Engineered Yeast Could Reduce Drug Shortages
Brewer’s yeast engineered with synthetic biology to produce drugs or raw materials could transform pharmaceutical supply chains.
Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines
Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains
We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic Chemistry in Pharma
Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
Antheia CEO on How Biomanufacturing can De-Risk Pharmaceutical Production
In a recent Q&A with European Pharmaceutical Manufacturer Antheia CEO and co-founder Dr. Christina Smolke discussed how latency and variability within agricultural supply chains remains the number one challenge in the pharmaceutical-grade production…
Antheia Announces New Financing and Plans to Construct Pilot Plant Facility for Biomanufacturing
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility.
Biomanufacturing draws hundreds of millions in investments
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology…
Antheia advances API biomanufacturing
Company’s SynBio platform enables manufacturing of complex plant-based drugs Biomanufacturing and synthetic biology (SynBio) manufacturing platforms have the potential to create more resilient supply chains for essential medicines by producing…
Investing in the next wave of biomanufacturing technologies for pharma
The global pandemic has brought pharmaceutical manufacturing to the forefront of America’s public consciousness. Acute drug shortages brought on by COVID-19 have underscored the need for domestic production and more resilient supply chains…
Scaling synthetic biology as a manufacturing platform
For decades, synthetic biology has promised to make manufacturing more efficient, sustainable, and responsive to sudden changes in supply and demand. It has the potential to create new value across industries by transforming everything from food to pharmaceuticals…